TI
VIR icon

Trexquant Investment’s Vir Biotechnology VIR Stock Holding History

Trexquant Investment’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$870K Sell
85,350
-9,417
-10% -$89.6K 0.01% 1501
2026
Q1 		$849K Buy
+94,767
New +$755K 0.01% 1285
2025
Q3 		– Sell
-217,355
Closed -$1.1M – 1941
2025
Q2 		$1.1M Buy
+217,355
New +$1.17M 0.01% 1082
2024
Q4 		– Sell
-196,991
Closed -$1.48M – 1875
2024
Q3 		$1.48M Buy
196,991
+94,688
+93% +$822K 0.02% 914
2024
Q2 		$910K Buy
+102,303
New +$981K 0.01% 1030
2023
Q1 		– Sell
-39,885
Closed -$1.01M – 1799
2022
Q4 		$1.01M Sell
39,885
-66,915
-63% -$1.64M 0.03% 640
2022
Q3 		$2.06M Buy
106,800
+68,060
+176% +$1.73M 0.07% 351
2022
Q2 		$987K Buy
38,740
+23,514
+154% +$549K 0.04% 526
2022
Q1 		$392K Buy
+15,226
New +$452K 0.02% 883
2021
Q1 		– Sell
-18,678
Closed -$500K – 1499
2020
Q4 		$500K Buy
18,678
+5,103
+38% +$166K 0.05% 451
2020
Q3 		$466K Buy
+13,575
New +$584K 0.03% 723

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Trexquant Investment's VIR Position: Q2 2026 in Review

Trexquant Investment reduced its Vir Biotechnology (VIR) stake by 9.9% in Q2 2026, selling an estimated $89.6K and leaving 85,350 shares worth $870K. The position accounts for 0.01% of the portfolio, ranked #1501.

Trexquant Investment first reported a position in VIR in Q3 2020 and has held it in 11 quarters since. The position peaked at $2.06M in Q3 2022. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Trexquant Investment held 85,350 shares of Vir Biotechnology worth $870K as of Q2 2026.
  • Trexquant Investment sold 9,417 Vir Biotechnology shares in Q2 2026, an estimated $89.6K.
  • Vir Biotechnology made up 0.01% of Trexquant Investment's portfolio in Q2 2026, its #1501 holding.
  • Trexquant Investment first reported a position in Vir Biotechnology in Q3 2020 and has held it in 11 quarters since.
  • Trexquant Investment's Vir Biotechnology position peaked at $2.06M in Q3 2022.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.